Carolyn Stahlhut
Adult Health · Lansdale, PANPI 1003811670
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (29.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 57.7% of the total. Reporting peaked in 2023 at $8,782 and has fallen 76.9% since, to $2,026 in 2025. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $116.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$14K
- Urovant Sciences Inc$5K
- Urogen Pharma, Inc.$1K
- Johnson & Johnson$504
- Astellas Pharma US Inc$345
- Dentsply IH AB$331
- plus $3K from 29 others
What the payments were for
- Consulting fees$6,38526%
- Speaking & faculty fees$5,13221%
- Travel & lodging$7,04029%
- Food & beverage$5,48023%
- Education$1791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 64 | $13,972 |
| Urovant Sciences Inc | 19 | $4,933 |
| Urogen Pharma, Inc. | 7 | $1,248 |
| Johnson & Johnson | 17 | $504 |
| Astellas Pharma US Inc | 12 | $345 |
| Dentsply IH AB | 12 | $331 |
| AstraZeneca | 3 | $329 |
| Boehringer Ingelheim | 3 | $259 |
| Bayer | 11 | $247 |
| 180 Medical, Inc. | 7 | $185 |
| Convatec Inc. | 4 | $149 |
| Coloplast | 7 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $143 |
| AbbVie | 6 | $133 |
| Gilead | 1 | $125 |
| Myriad Genetic Laboratories, Inc. | 6 | $119 |
| Teleflex LLC | 5 | $115 |
| Esperion Therapeutics, Inc. | 1 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $99 |
| Inspire Medical Systems, Inc. | 1 | $90 |
| Insmed, Inc. | 1 | $87 |
| Dentsply IH Inc. | 2 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $77 |
| Abbott | 1 | $68 |
| Pfizer | 2 | $44 |
| Telix Pharmaceuticals | 2 | $40 |
| GSK | 1 | $38 |
| ABC Home Medical Supply, Inc. | 1 | $35 |
| Progenics Pharmaceuticals, Inc. | 1 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Blue Earth Diagnostics | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Boston Scientific | 1 | $15 |
| Myovant Sciences Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,215 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $161,029 |
| MyrbetriqMirabegron | 156 | $106,928 |
| GemtesaVibegron | 78 | $66,676 |
| Methenamine Hippurate | 84 | $9,102 |
| Tamsulosin Hcl | 487 | $6,534 |
| Estradiol | 79 | $4,957 |
| Tolterodine Tartrate ErTolterodine Tartrate | 59 | $4,602 |
| Solifenacin Succinate | 85 | $3,818 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 131 | $3,209 |
| Finasteride | 182 | $2,869 |
| Dutasteride | 53 | $2,494 |
| Oxybutynin Chloride ErOxybutynin Chloride | 96 | $2,346 |
| Testosterone | 13 | $1,971 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 119 | $1,808 |
| Silodosin | 18 | $1,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $345 | $267,957168 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $13,972 | $66,67678 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Lansdale
- Beth SandyPhiladelphia$924K
- Jennifer MondilloSchwenksville$396K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
- Catherine HoldsworthPhiladelphia$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.